Effects of varenicline on abstinence and smoking reward following a programmed lapse.

Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco
Erin A McClureMaxine L Stitzer

Abstract

Varenicline (Chantix®) is an efficacious first-line medication for smoking cessation. Studies suggest that one mechanism by which varenicline facilitates sustained smoking abstinence is by reducing the likelihood of relapse to smoking when a lapse, or slip, occurs during a quit attempt. The present study extends this line of research by conducting a prospective laboratory study to examine the relapse prevention effects of varenicline following a programmed lapse. Daily smokers (N = 47) completed a 5-week outpatient study in which they were randomized to receive varenicline or placebo. The first week was a medication induction period that was immediately followed by a 4-week quit attempt. A programmed lapse (2 cigarettes smoked in the laboratory) occurred on the second day of the quit attempt. Participants receiving varenicline were slower to relapse and had greater total abstinence rates following lapse exposure. Participants in the varenicline group rated lapse cigarettes lower on measures of reward and intoxication and showed increased behavioral economic demand elasticity for cigarettes (reduced cigarette purchasing at higher prices) compared with those receiving placebo. These results demonstrate a relapse prevention effect...Continue Reading

References

Jan 1, 1992·Psychopharmacology·W M ChornockS Leischow
Sep 1, 1991·British Journal of Addiction·T F HeathertonK O Fagerström
Jan 1, 1990·Addictive Behaviors·T H BrandonT B Baker
Jun 1, 1988·Journal of Personality and Social Psychology·D WatsonA Tellegen
Mar 1, 1986·Archives of General Psychiatry·J R Hughes, D Hatsukami
Mar 1, 1995·Psychopharmacology·P WillnerG Eaton
Nov 1, 1993·Comprehensive Psychiatry·J J HudziakT Przybeck
Aug 1, 1995·Psychopharmacology·K J Schuh, M L Stitzer
Apr 1, 1997·Psychopharmacology·Y ShahamW A Corrigall
May 18, 1999·Addiction·N M Petry, W K Bickel
Dec 22, 1999·Journal of the Experimental Analysis of Behavior·W K Bickel, G J Madden
Dec 23, 2003·Journal of General Internal Medicine·John R Hughes
Feb 26, 2005·Molecular Interventions·Steven R HurshJames H Woods
Feb 10, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·A D LêY Shaham
Feb 24, 2006·Journal of Abnormal Psychology·Laura M JulianoMaxine L Stitzer
Apr 11, 2006·Journal of the Experimental Analysis of Behavior·Matthew W Johnson, Warren K Bickel
Jun 8, 2006·Experimental and Clinical Psychopharmacology·James G Murphy, James MacKillop
Jul 6, 2006·JAMA : the Journal of the American Medical Association·David GonzalesUNKNOWN Varenicline Phase 3 Study Group
Jul 6, 2006·JAMA : the Journal of the American Medical Association·Douglas E JorenbyUNKNOWN Varenicline Phase 3 Study Group
Nov 23, 2006·Experimental and Clinical Psychopharmacology·Laura M JulianoMaxine L Stitzer
May 18, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Megan J ShramAnh D Lê
Jun 19, 2007·Trends in Pharmacological Sciences·Hans RollemaKathryn E Williams
Jan 24, 2008·Psychological Review·Steven R Hursh, Alan Silberberg
Feb 13, 2008·Experimental and Clinical Psychopharmacology·James MacKillopDavid S Wilson
Aug 30, 2008·The International Journal of Neuropsychopharmacology·Elena Martín-GarcíaRafael Maldonado
Oct 10, 2008·Biological Psychiatry·Freda PattersonCaryn Lerman
May 16, 2009·Drug and Alcohol Dependence·Lawrence P Carter, Roland R Griffiths
Dec 9, 2009·Experimental and Clinical Psychopharmacology·James G MurphyAshley A Pederson
Mar 3, 2010·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Gregory J Madden, David Kalman
Nov 9, 2010·Clinical Pharmacokinetics·Hélène M FaesselAaron H Burstein
Feb 18, 2011·The Cochrane Database of Systematic Reviews·Kate CahillTim Lancaster
May 12, 2011·Psychopharmacology·Thomas H BrandonBrent J Small

❮ Previous
Next ❯

Citations

Dec 12, 2012·Psychopharmacology·Henry W ChaseLee Hogarth
Nov 13, 2013·Psychopharmacology·Natalie R Bruner, Matthew W Johnson
Apr 1, 2014·Annual Review of Clinical Psychology·Warren K BickelJames G Murphy
Jul 30, 2014·Proceedings of the National Academy of Sciences of the United States of America·Brandon S BentzleyGary Aston-Jones
Jun 21, 2014·Addictive Behaviors·Nicolas J SchlienzMartin C Mahoney
Jul 26, 2014·The American Journal of Drug and Alcohol Abuse·Erin A McClureKevin M Gray
May 11, 2016·Current Addiction Reports·Daniel J O RocheAndrea C King
Mar 5, 2016·Addiction Biology·Brandon S Bentzley, Gary Aston-Jones
Jun 4, 2014·Alcoholism, Clinical and Experimental Research·Michael Amlung, James MacKillop
Apr 7, 2016·Psychopharmacology·Richard J O'ConnorK Michael Cummings
Jul 13, 2016·Journal of the Experimental Analysis of Behavior·Derek D ReedSteven R Hursh
Jun 15, 2017·Journal of Psychopharmacology·Matthew W JohnsonLauren R Pacek
Jan 10, 2018·Addiction Biology·James MacKillopAdam M Leventhal
Sep 25, 2019·International Journal of Environmental Research and Public Health·Lauren R PacekMatthew W Johnson
Feb 15, 2020·Journal of the Experimental Analysis of Behavior·Justin C StricklandB Levi Bolin
May 10, 2016·The Cochrane Database of Systematic Reviews·Kate CahillTim Lancaster
Feb 15, 2021·Drug and Alcohol Dependence·Elizabeth R AstonSamantha G Farris
Feb 16, 2021·Journal of the Experimental Analysis of Behavior·Lindsay P SchwartzSteven R Hursh
Mar 30, 2017·Behavioural Processes·Justin C StricklandWilliam W Stoops
Jul 2, 2021·Drug and Alcohol Dependence·Jin H YoonJoy M Schmitz

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.